<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032025000400394</article-id>
<article-id pub-id-type="doi">10.35366/120525</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia dual de quimioembolización transarterial y atezolizumab más bevacizumab para carcinoma hepatocelular fibrolamelar irresecable]]></article-title>
<article-title xml:lang="en"><![CDATA[Dual therapy of transarterial chemoembolization and atezolizumab plus bevacizumab for unresectable fibrolamellar hepatocellular carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Espinoza]]></surname>
<given-names><![CDATA[Iván Romarico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miguel Cruz]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro Ponce]]></surname>
<given-names><![CDATA[Abraham]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta Ponce de León]]></surname>
<given-names><![CDATA[Eric]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Sosa]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz Ibarra]]></surname>
<given-names><![CDATA[Gustavo Adolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quesnel Samperio]]></surname>
<given-names><![CDATA[Alondra Jolie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Angeles Puebla  ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Angeles Puebla  ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Angeles Puebla  ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Angeles Puebla  ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Angeles Puebla  ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad de las Américas Puebla Servicio Social ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>23</volume>
<numero>4</numero>
<fpage>394</fpage>
<lpage>396</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032025000400394&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032025000400394&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032025000400394&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El carcinoma hepatocelular fibrolamelar (CHF) es una forma rara de hepatocarcinoma que afecta a pacientes jóvenes. Aquí presentamos un caso de CHF no resecable tratado con quimioembolización transarterial y una combinación de atezolizumab y bevacizumab.  Descripción del caso:  Mujer de 20 años con dolor abdominal, náuseas y vómitos, fue diagnosticada con CHF bien diferenciado. Se implementó un régimen terapéutico dual, logrando una reducción del tamaño de la lesión del 26.7%, mantenida por 18.13 meses. La supervivencia global fue de 22.23 meses.  Conclusión:  El CHF difiere del carcinoma hepatocelular convencional y presenta desafíos terapéuticos. La combinación de quimioembolización e inmunoterapia muestra un potencial prometedor. Este caso añade información valiosa sobre el CHF en nuestro país.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of hepatocellular carcinoma affecting young patients. We present a case of unresectable FLC treated with transarterial chemoembolization and a combination of atezolizumab and bevacizumab.  Case description:  A 20-year-old woman with abdominal pain, nausea, and vomiting was diagnosed with well-differentiated FLC. A dual therapy regimen was implemented, achieving a 26.7% reduction in lesion size, maintained for 18.13 months. The overall survival was 22.23 months.  Conclusion:  FLC differs from conventional hepatocellular carcinoma and presents therapeutic challenges. The combination of chemoembolization and immunotherapy shows promising potential. This case adds valuable information about FLC in our country.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hepatocarcinoma fibrolamelar]]></kwd>
<kwd lng="es"><![CDATA[quimioembolización]]></kwd>
<kwd lng="es"><![CDATA[atezolizumab]]></kwd>
<kwd lng="es"><![CDATA[bevacizumab]]></kwd>
<kwd lng="en"><![CDATA[fibrolamellar carcinoma]]></kwd>
<kwd lng="en"><![CDATA[chemoembolization]]></kwd>
<kwd lng="en"><![CDATA[atezolizumab]]></kwd>
<kwd lng="en"><![CDATA[bevacizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelhamed]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[El-Kassas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event]]></article-title>
<source><![CDATA[World J Gastrointest Oncol]]></source>
<year>2022</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1103-14</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Edmondson]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Omata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1980</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>372-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrolamellar Carcinoma: a concise review]]></article-title>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>2018</year>
<volume>142</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1141-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kohler]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maringer]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bucher]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bilich]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zwick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma]]></article-title>
<source><![CDATA[Nat Commun]]></source>
<year>2022</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6401</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernon]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Allam]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kloppers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jonas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trans-arterial therapy for fibrolamellar carcinoma: a case report and literature review]]></article-title>
<source><![CDATA[Int J Surg Case Rep]]></source>
<year>2022</year>
<volume>94</volume>
<page-range>106980</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
